menu
    • menu
    [{"orgOrder":0,"company":"GE Healthcare","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"GE Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GE Healthcare \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"GE Healthcare \/ Covance"},{"orgOrder":0,"company":"AnaCardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AC01","moa":"Amyloid-beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"AnaCardio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AnaCardio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AnaCardio \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Itochu Chemical Frontier","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Itochu Chemical Frontier","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Itochu Chemical Frontier"},{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.59999999999999998,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Novo Nordisk","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Novo Nordisk"},{"orgOrder":0,"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Heartseed \/ UTokyo Innovation Platform","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ UTokyo Innovation Platform"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Heartseed \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ALN-APOC3","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ikaria Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RN0361","moa":"APOC-3 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Ikaria Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ikaria Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ikaria Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MDCO-216","moa":"Apolipoprotein A-I (APOA1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"The Medicines Company \/ Cleveland Clinic"},{"orgOrder":0,"company":"LipimetiX Development","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"AEM-28","moa":"Apolipoprotein E (APOE)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"LipimetiX Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LipimetiX Development \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"LipimetiX Development \/ Undisclosed"},{"orgOrder":0,"company":"Inserm","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"99m-Tc Annexin V-128","moa":"Apoptosis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"7","companyTruncated":"Inserm \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"hPSC-CM","moa":"Cardiac ion channels","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Help Therapeutics \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"MyoKardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyoKardia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MyoKardia \/ Undisclosed"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"iPSC-Derived Cardiomyocytes","moa":"Cardiomyocytes","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Help Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Financing","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ K2 HealthVentures","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ K2 HealthVentures"},{"orgOrder":0,"company":"Medis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SLOVENIA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Endometrial Regenerative Cell","moa":"Endometrial tissue","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medis \/ Undisclosed"},{"orgOrder":0,"company":"Thrombotech Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"THR-18","moa":"Endothelial plasminogen activator inhibitor (SERPINE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thrombotech Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thrombotech Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thrombotech Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SLOVENIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Greenstone Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Centre Ljubljana \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DS-1040b","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DS-1040b","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DS-1040b","moa":"Factor XI","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Swiss National Science Foundation | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Zurich \/ Swiss National Science Foundation | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Zurich \/ Swiss National Science Foundation | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Private Placement","leadProduct":"LX2006","moa":"FXN","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Frazier Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Frazier Life Sciences"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Stanford University | Greenstone Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SLOVENIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Stanford University | Greenstone Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Centre Ljubljana \/ Stanford University | Greenstone Biosciences"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Amino Acid","year":"2010","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"New Beta Innovation Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"YQ23","moa":"Hemoglobins","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"New Beta Innovation Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New Beta Innovation Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"New Beta Innovation Limited \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Grazoprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"University of Pennsylvania \/ Merck & Co"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Academy Military Medical Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ad-Hgf","moa":"HGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Academy Military Medical Science","highestDevelopmentStatusID":"7","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Academy Military Medical Science"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Rochester \/ Pfizer Inc"},{"orgOrder":0,"company":"Xintela","sponsor":"Vinnova","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Xstem-Vlu","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Xintela","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xintela \/ Vinnova","highestDevelopmentStatusID":"7","companyTruncated":"Xintela \/ Vinnova"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Secretome","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Prodia StemCell Indonesia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PT Prodia StemCell Indonesia \/ Undisclosed"},{"orgOrder":0,"company":"Helios Cardio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Amiodarine","moa":"Ion Channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Helios Cardio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Helios Cardio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helios Cardio \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai JMT-Bio Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"JMT202","moa":"Klotho beta","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Shanghai JMT-Bio Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai JMT-Bio Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai JMT-Bio Inc. \/ Undisclosed"},{"orgOrder":0,"company":"HighTide Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"HTD1801","moa":"Lipid","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"HighTide Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HighTide Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HighTide Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jiuzhitang Maker Cell Technology","sponsor":"Beijing Tiantan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"it-hMSC","moa":"Mesenchymal stem cells","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Jiuzhitang Maker Cell Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jiuzhitang Maker Cell Technology \/ Beijing Tiantan Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jiuzhitang Maker Cell Technology \/ Beijing Tiantan Hospital"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TRC150094","moa":"Mitochondrial function","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Torrent Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Washington University School of Medicine | Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Washington University School of Medicine | Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ Washington University School of Medicine | Cleveland Clinic"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"University of Virginia | Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Atibuclimab","moa":"Monocyte differentiation antigen CD14","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Implicit Bioscience \/ University of Virginia | Virginia Commonwealth University","highestDevelopmentStatusID":"7","companyTruncated":"Implicit Bioscience \/ University of Virginia | Virginia Commonwealth University"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Tenaya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tenaya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tenaya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Boulder","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Colorado, Boulder","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Boulder \/ ChromaDex, Inc","highestDevelopmentStatusID":"7","companyTruncated":"University of Colorado, Boulder \/ ChromaDex, Inc"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Gateway Health Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, Davis \/ Gateway Health Alliance","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Davis \/ Gateway Health Alliance"},{"orgOrder":0,"company":"Innervate Radiopharmaceuticals","sponsor":"Mount Sinai Hospital, New York","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F MFBG","moa":"Norepinephrine transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Innervate Radiopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innervate Radiopharmaceuticals \/ Mount Sinai Hospital, New York","highestDevelopmentStatusID":"7","companyTruncated":"Innervate Radiopharmaceuticals \/ Mount Sinai Hospital, New York"},{"orgOrder":0,"company":"Laval University","sponsor":"Canadian Institutes of Health Research | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Canadian Institutes of Health Research | AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Laval University \/ Canadian Institutes of Health Research | AstraZeneca"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ITI214","moa":"PDE1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Cardiora","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CRD-102","moa":"PDE3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cardiora","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardiora \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cardiora \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ITI214","moa":"Phosphodiesterase 1 (PDE1)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Milrinone","moa":"Phosphodiesterase 3A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Baker Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Baker Institute \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Baker Institute \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"National Heart, Lung, and Blood Institute | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ National Heart, Lung, and Blood Institute | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vanderbilt University Medical Center \/ National Heart, Lung, and Blood Institute | Pfizer Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tadalafil","moa":"Phosphodiesterase 5A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Acticor Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ACT017","moa":"Platelet glycoprotein VI (GPVI)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Acticor Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acticor Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Acticor Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Coretherapix","sponsor":"European Commission | Universitaire Ziekenhuizen KU Leuven | Saint-Louis Hospital, Paris | Hospital General Universitario Gregorio Mara\u00f1on | Complejo Hospitalario de Navarra | Hospital Cl\u00ednico Universitario de Valladolid | Hospital Donostia | Hospital Cl\u00ed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Allogeneic Human Cardiac Stem Cell","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Coretherapix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coretherapix \/ European Commission | Universitaire Ziekenhuizen KU Leuven | Saint-Louis Hospital, Paris | Hospital General Universitario Gregorio Mara\u00f1on | Complejo Hospitalario de Navarra | Hospital Cl\u00ednico Universitario de Valladolid | Hospital Donostia | Hospital Cl\u00ed","highestDevelopmentStatusID":"7","companyTruncated":"Coretherapix \/ European Commission | Universitaire Ziekenhuizen KU Leuven | Saint-Louis Hospital, Paris | Hospital General Universitario Gregorio Mara\u00f1on | Complejo Hospitalario de Navarra | Hospital Cl\u00ednico Universitario de Valladolid | Hospital Donostia | Hospital Cl\u00ed"},{"orgOrder":0,"company":"Southern Medical University","sponsor":"The Second People's Hospital of Nanhai District of Foshan | The First People's Hospital of Haizhu District Guangzhou | Cellonis Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Bone Marrow Mesenchymal Stem Cell","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Southern Medical University \/ The Second People's Hospital of Nanhai District of Foshan | The First People's Hospital of Haizhu District Guangzhou | Cellonis Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Southern Medical University \/ The Second People's Hospital of Nanhai District of Foshan | The First People's Hospital of Haizhu District Guangzhou | Cellonis Biotechnology"},{"orgOrder":0,"company":"Academy Military Medical Science","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Bmmscs","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Academy Military Medical Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academy Military Medical Science \/ Sun Yat-sen University","highestDevelopmentStatusID":"7","companyTruncated":"Academy Military Medical Science \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Harvest Technologies","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Bone Marrow Aspirate Concentrate","moa":"Progenitor cell","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Harvest Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harvest Technologies \/ University of Utah","highestDevelopmentStatusID":"7","companyTruncated":"Harvest Technologies \/ University of Utah"},{"orgOrder":0,"company":"Thrombologic ApS","sponsor":"Lene Holmvang | Rigshospitalet","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thrombologic ApS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thrombologic ApS \/ Lene Holmvang | Rigshospitalet","highestDevelopmentStatusID":"7","companyTruncated":"Thrombologic ApS \/ Lene Holmvang | Rigshospitalet"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Pharmaceuticals Holding Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SPH3127","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Shanghai Pharmaceuticals Holding Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Pharmaceuticals Holding Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Celladon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Mydicar","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase 2 (ATP2A2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Celladon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celladon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Celladon \/ Undisclosed"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dofetilide","moa":"||SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islasertib","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Islasertib","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Investissement Qu\u00e9bec","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Investissement Qu\u00e9bec"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LQT-1213","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LQT-1213","moa":"SGK1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thryv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thryv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thryv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SQ Innovation","sponsor":"Accel Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"SQ Innovation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SQ Innovation \/ Accel Clinical Services","highestDevelopmentStatusID":"7","companyTruncated":"SQ Innovation \/ Accel Clinical Services"},{"orgOrder":0,"company":"Neogenis Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Neogenis Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Neogenis Laboratories \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Neogenis Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Sclnow Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sclnow Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sclnow Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sclnow Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"University of Rochester","sponsor":"GSK | Albany College of Pharmacy and Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Rochester \/ GSK | Albany College of Pharmacy and Health Sciences","highestDevelopmentStatusID":"7","companyTruncated":"University of Rochester \/ GSK | Albany College of Pharmacy and Health Sciences"},{"orgOrder":0,"company":"aptaTargets","sponsor":"Ministry of Science and Innovation, Spain | Anagram Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aptoll","moa":"TLR4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"aptaTargets","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"aptaTargets \/ Ministry of Science and Innovation, Spain | Anagram Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"aptaTargets \/ Ministry of Science and Innovation, Spain | Anagram Therapeutics"},{"orgOrder":0,"company":"aptaTargets","sponsor":"Ministry of Science and Innovation, Spain | Anagram Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aptoll","moa":"TLR4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"aptaTargets","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"aptaTargets \/ Ministry of Science and Innovation, Spain | Anagram Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"aptaTargets \/ Ministry of Science and Innovation, Spain | Anagram Therapeutics"},{"orgOrder":0,"company":"aptaTargets","sponsor":"Centro para el Desarrollo Tecnol\u00f3gico Industrial","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Aptoll","moa":"TLR4","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"aptaTargets","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"aptaTargets \/ Centro para el Desarrollo Tecnol\u00f3gico Industrial","highestDevelopmentStatusID":"7","companyTruncated":"aptaTargets \/ Centro para el Desarrollo Tecnol\u00f3gico Industrial"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"TTR","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"YolTech Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"YolTech Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Texas Medical Branch, Galveston","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Texas Medical Branch, Galveston","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Texas Medical Branch, Galveston \/ Lantheus Medical Imaging","highestDevelopmentStatusID":"7","companyTruncated":"University of Texas Medical Branch, Galveston \/ Lantheus Medical Imaging"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"University of Missouri-Columbia","sponsor":"Sagimet Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"3-V Bioscience-2640","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University of Missouri-Columbia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Missouri-Columbia \/ Sagimet Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"University of Missouri-Columbia \/ Sagimet Biosciences"},{"orgOrder":0,"company":"Affiliated Hospital of Nantong University","sponsor":"Nantong Shengyuan Stem Cell Techology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ABMSC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Affiliated Hospital of Nantong University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiliated Hospital of Nantong University \/ Nantong Shengyuan Stem Cell Techology Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Affiliated Hospital of Nantong University \/ Nantong Shengyuan Stem Cell Techology Co., Ltd"},{"orgOrder":0,"company":"S.Biomedics","sponsor":"Dt&Sanomedics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"S.Biomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.Biomedics \/ Dt&Sanomedics","highestDevelopmentStatusID":"7","companyTruncated":"S.Biomedics \/ Dt&Sanomedics"},{"orgOrder":0,"company":"RHEACELL","sponsor":"FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"allo-APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ FGK Clinical Research | Ticeba GmbH | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Allogeneic Adult Mesenchymal Bone Marrow Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemedica Cell Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica Cell Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Capricor","sponsor":"National Institutes of Health | National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-Derived Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor \/ National Institutes of Health | National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"7","companyTruncated":"Capricor \/ National Institutes of Health | National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"University of California, San Diego | Mercy Gilbert Medical Center | Chandler Regional Medical Center at Chandler AZ | UCI Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemedica Cell Technologies \/ University of California, San Diego | Mercy Gilbert Medical Center | Chandler Regional Medical Center at Chandler AZ | UCI Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica Cell Technologies \/ University of California, San Diego | Mercy Gilbert Medical Center | Chandler Regional Medical Center at Chandler AZ | UCI Medical Center"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"AMDC","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook MyoSite \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cook MyoSite \/ Undisclosed"},{"orgOrder":0,"company":"RHEACELL","sponsor":"Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"APZ2","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"RHEACELL","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RHEACELL \/ Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting","highestDevelopmentStatusID":"7","companyTruncated":"RHEACELL \/ Ticeba GmbH | FGK Clinical Research | Granzer Regulatory Consulting"},{"orgOrder":0,"company":"James Baumgartner","sponsor":"Cord Blood Registry","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Cord Blood Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"James Baumgartner","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"James Baumgartner \/ Cord Blood Registry","highestDevelopmentStatusID":"7","companyTruncated":"James Baumgartner \/ Cord Blood Registry"},{"orgOrder":0,"company":"Kasiak Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Autologous Stromal Vascular Fraction","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Kasiak Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kasiak Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kasiak Research \/ Undisclosed"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2022","type":"Financing","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Marius Nacht","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Marius Nacht"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BioGenCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Undisclosed"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Laniado Hospital | Rabin Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"BGC101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioGenCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioGenCell \/ Laniado Hospital | Rabin Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"BioGenCell \/ Laniado Hospital | Rabin Medical Center"},{"orgOrder":0,"company":"Griffin Hospital","sponsor":"NSA, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Blend","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Griffin Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffin Hospital \/ NSA, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Griffin Hospital \/ NSA, LLC"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Bone Marrow-derived Mesenchymal Stem Cells","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Bone Marrow-derived Mesenchymal Stem Cells","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Bone Marrow-derived Mesenchymal Stem Cells","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Cardiopressin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Thorne HealthTech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Thorne HealthTech \/ Undisclosed"},{"orgOrder":0,"company":"Cardix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CARDIX-101","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cardix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cardix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cardix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Repairon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Engineered Heart Muscle","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Repairon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Repairon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Repairon \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Goettingen","sponsor":"Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | University Medical Center Freiburg | Repairon GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Engineered Human Myocardium","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"University Medical Center Goettingen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"University Medical Center Goettingen \/ Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | University Medical Center Freiburg | Repairon GmbH","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Center Goettingen \/ Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung | University Medical Center Freiburg | Repairon GmbH"},{"orgOrder":0,"company":"Hexun Biosciences Co.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"HeXell-2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Hexun Biosciences Co.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hexun Biosciences Co. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hexun Biosciences Co. \/ Undisclosed"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"TEDA International Cardiovascular Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HiCM-188","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Help Therapeutics \/ TEDA International Cardiovascular Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ TEDA International Cardiovascular Hospital"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HiCM-188","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Help Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HiCM-188","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Help Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Help Therapeutics","sponsor":"Shanghai East Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"hiPSC-CM","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Help Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Help Therapeutics \/ Shanghai East Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Help Therapeutics \/ Shanghai East Hospital"},{"orgOrder":0,"company":"Cellcolabs Clinical LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cellcolabs Clinical LTD.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellcolabs Clinical LTD. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cellcolabs Clinical LTD. \/ Undisclosed"},{"orgOrder":0,"company":"BioCardia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Allogenic Culture Bone Marrow-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioCardia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioCardia \/ Undisclosed"},{"orgOrder":0,"company":"Affiliated Hospital to Academy of Military Medical Sciences","sponsor":"Ivy Institute of Stem Cells Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Affiliated Hospital to Academy of Military Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd"},{"orgOrder":0,"company":"Ankara University","sponsor":"Hacettepe University | Turkiye Yuksek Ihtisas Education and Research Hospital | Atigen-Cell and Tissue Center | Dr. Sami Ulus Children's Hospital | Ankara Yildirim Beyaz?t University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TURKEY","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Human Umbilical Cord Stroma Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Ankara University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ankara University \/ Hacettepe University | Turkiye Yuksek Ihtisas Education and Research Hospital | Atigen-Cell and Tissue Center | Dr. Sami Ulus Children's Hospital | Ankara Yildirim Beyaz?t University","highestDevelopmentStatusID":"7","companyTruncated":"Ankara University \/ Hacettepe University | Turkiye Yuksek Ihtisas Education and Research Hospital | Atigen-Cell and Tissue Center | Dr. Sami Ulus Children's Hospital | Ankara Yildirim Beyaz?t University"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Icodextrin","moa":"||Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Icodextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"Xuanwu Hospital, Beijing","sponsor":"Wiseheart Co.Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"iNSC-EV01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Xuanwu Hospital, Beijing","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xuanwu Hospital, Beijing \/ Wiseheart Co.Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Xuanwu Hospital, Beijing \/ Wiseheart Co.Ltd"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Grifols International | Dysautonomia International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"IVIG","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Grifols International | Dysautonomia International","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ Grifols International | Dysautonomia International"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"JTR-161","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Teijin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Teijin Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Teijin Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2020","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lexeo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RMJ Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Magnesium Citrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"RMJ Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RMJ Holdings \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"RMJ Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"GENERAL ELECTRIC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Manganese-Enhanced Mri Contrast Reagent","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ GENERAL ELECTRIC","highestDevelopmentStatusID":"7","companyTruncated":"Stanford University \/ GENERAL ELECTRIC"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Prodia StemCell Indonesia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PT Prodia StemCell Indonesia \/ Undisclosed"},{"orgOrder":0,"company":"Stempeutics","sponsor":"Stempeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Stempeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stempeutics \/ Stempeutics","highestDevelopmentStatusID":"7","companyTruncated":"Stempeutics \/ Stempeutics"},{"orgOrder":0,"company":"UMC Utrecht","sponsor":"ZonMw | MD Anderson Cancer Center | University of Texas Health Science Center at San Antonio","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"UMC Utrecht","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMC Utrecht \/ ZonMw | MD Anderson Cancer Center | University of Texas Health Science Center at San Antonio","highestDevelopmentStatusID":"7","companyTruncated":"UMC Utrecht \/ ZonMw | MD Anderson Cancer Center | University of Texas Health Science Center at San Antonio"},{"orgOrder":0,"company":"Honya Medical","sponsor":"Chung Shan Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Misaver Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Honya Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Honya Medical \/ Chung Shan Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Honya Medical \/ Chung Shan Medical University"},{"orgOrder":0,"company":"Microvascular Therapeutics","sponsor":"National Heart, Lung, and Blood Institute | University of Nebraska","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MVT-100","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Microvascular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Microvascular Therapeutics \/ National Heart, Lung, and Blood Institute | University of Nebraska","highestDevelopmentStatusID":"7","companyTruncated":"Microvascular Therapeutics \/ National Heart, Lung, and Blood Institute | University of Nebraska"},{"orgOrder":0,"company":"NC Medial Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"NCS-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"NC Medial Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NC Medial Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NC Medial Research \/ Undisclosed"},{"orgOrder":0,"company":"Hitachi Chemical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Non-Hemapoietic Bone-Marrow Derived Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hitachi Chemical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Chemical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Cardiologia do Rio Grande do Sul","sponsor":"Quaker Oats Company | CNPq Universal","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Oat Bran","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Instituto de Cardiologia do Rio Grande do Sul","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Cardiologia do Rio Grande do Sul \/ Quaker Oats Company | CNPq Universal","highestDevelopmentStatusID":"7","companyTruncated":"Instituto de Cardiologia do Rio Grande do Sul \/ Quaker Oats Company | CNPq Universal"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PF-07868489","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chandra Duggirala","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Plasma Transfusion","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Chandra Duggirala","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chandra Duggirala \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chandra Duggirala \/ Undisclosed"},{"orgOrder":0,"company":"Iperboreal Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Polydextrin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Iperboreal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Iperboreal Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iperboreal Pharma \/ Undisclosed"},{"orgOrder":0,"company":"4TEEN4 Pharmaceuticals GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Procizumab","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"4TEEN4 Pharmaceuticals GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4TEEN4 Pharmaceuticals GmbH \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"4TEEN4 Pharmaceuticals GmbH \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PVS-10200","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"SHR-1209","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Sulfagenix Australia Pty Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Sodium Polysulfide","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Sulfagenix Australia Pty Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sulfagenix Australia Pty Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sulfagenix Australia Pty Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Serpin Pharma, LLC","sponsor":"Virginia Commonwealth University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SP16","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Serpin Pharma, LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serpin Pharma, LLC \/ Virginia Commonwealth University","highestDevelopmentStatusID":"7","companyTruncated":"Serpin Pharma, LLC \/ Virginia Commonwealth University"},{"orgOrder":0,"company":"Medera","sponsor":"CADENCE","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medera \/ CADENCE","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ CADENCE"},{"orgOrder":0,"company":"Medera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ Undisclosed"},{"orgOrder":0,"company":"Medera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ Undisclosed"},{"orgOrder":0,"company":"Medera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medera \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medera \/ Undisclosed"},{"orgOrder":0,"company":"Chantal Blok","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Tiscover","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Chantal Blok","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chantal Blok \/ ZonMw","highestDevelopmentStatusID":"7","companyTruncated":"Chantal Blok \/ ZonMw"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"VAL070-A","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"7","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Beijing Inno Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YN001","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Beijing Inno Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Inno Medicine \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Inno Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Navitas Inc","sponsor":"IndiPharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Cicletanine","moa":"Vasodilator","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Navitas Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitas Inc \/ IndiPharm","highestDevelopmentStatusID":"7","companyTruncated":"Navitas Inc \/ IndiPharm"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"AdVEGFXC1","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series A Financing","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Fountain Healthcare Partners"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"XyloCor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series B Financing","leadProduct":"Encoberminogene Rezmadenovec","moa":"VEGF gene producer","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"XyloCor Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Longeveron","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"VEGF receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Longeveron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longeveron \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Longeveron \/ Undisclosed"},{"orgOrder":0,"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2025","type":"Termination","leadProduct":"HS-001","moa":"Angiogenic factor secretion","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Heartseed","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Heartseed \/ Novo Nordisk","highestDevelopmentStatusID":"7","companyTruncated":"Heartseed \/ Novo Nordisk"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Anfibatide","moa":"Platelet glycoprotein Ib alpha chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Repairon GmbH","sponsor":"Bioventure Management GmbH","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Repairon GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Repairon GmbH \/ Bioventure Management GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Repairon GmbH \/ Bioventure Management GmbH"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Repairon GmbH

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Repairon GmbH

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bioventure Management GmbH

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Repairon Secures Funding to Advance Regenerative Heart Therapy for Advanced Heart Failure

                            Details : The collaboration aims to advance regenerative therapy for advanced heart failure through the development of lab-engineered cardiac cell sheets.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 02, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bioventure Management GmbH

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Heartseed

                            Japan arrow
                            AllPack Indonesia
                            Not Confirmed

                            Heartseed

                            Japan arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HS-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $598.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Novo calls off $598M Heartseed collab, citing 'strategic reviews'

                            Details : Novo Nordisk has axed a cell therapy collaboration with Heartseed, on its allogeneic cell therapy, HS-001, designed to restore heart muscle and function for patients with advanced heart failure.

                            Product Name : HS-001

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $55.0 million

                            September 30, 2025

                            Lead Product(s) : HS-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novo Nordisk

                            Deal Size : $598.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xuanwu Hospital, Beijing

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Xuanwu Hospital, Beijing

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iNSC-EV01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Wiseheart Co.Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke

                            Details : INSC-EV01 is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 27, 2025

                            Lead Product(s) : iNSC-EV01

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Wiseheart Co.Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai JMT-Bio Inc.

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Shanghai JMT-Bio Inc.

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JMT202

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            a Phase 1b/2a Study of JMT202 Injection in Participants with Hypertriglyceridemia

                            Details : JMT202 is a Antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Hypertriglyceridemia.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : JMT202

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hexun Biosciences Co.

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Hexun Biosciences Co.

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HeXell-2020

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HeXell-2020 Stem Cells Safety In Stable Coronary Artery Disease

                            Details : HeXell-2020 is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Coronary Artery Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 22, 2025

                            Lead Product(s) : HeXell-2020

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Affiliated Hospital of Nantong University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Affiliated Hospital of Nantong University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABMSC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Nantong Shengyuan Stem Cell Techology Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke

                            Details : ABMSC is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Ischemic Stroke.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 31, 2025

                            Lead Product(s) : ABMSC

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Nantong Shengyuan Stem Cell Techology Co., Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lexeo Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Frazier Life Sciences

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lexeo Raises $80M to Advance Genetic Medicines for Cardiovascular Diseases

                            Details : Lexeo intends to use net proceeds to fund advancement of ongoing clinical stage programs, including LX2006, a gene therapy candidate designed to deliver a functional frataxin.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 27, 2025

                            Lead Product(s) : LX2006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Frazier Life Sciences

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioCardia

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            BioCardia

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bone Marrow-derived Mesenchymal Stem Cells

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioCardia gets Positive DSMB Review for CardiALLO Cell Therapy Trial

                            Details : CardiALLO (Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cell) is under phase 1/2 clinical development for the treatment of ischemic heart failure of reduced ejection fraction.

                            Product Name : CardiALLO

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Bone Marrow-derived Mesenchymal Stem Cells

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lexeo Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Lexeo Therapeutics

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX2006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lexeo Reports Positive Interim Data for LX2006 in Friedreich Ataxia

                            Details : LX2006 is an AAV-based gene therapy candidate. Currently, it is being evaluated for the treatment of Friedreich Ataxia cardiomyopathy.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 07, 2025

                            Lead Product(s) : LX2006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Medera

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Medera

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SRD-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medera gets DSMB Clearance for SRD-001 Gene Therapy in Heart Failure

                            Details : SRD-001 is an adeno-associated virus mediated gene transfer that contains an engineered version of the SERCA2a gene for the treatment of heart failure.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 20, 2025

                            Lead Product(s) : SRD-001

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth